Clinical trial

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05425862

Study summary

ClinicalTrials.gov

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: SUSPENDED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Pidnarulex Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Talazoparib Normalized identity: talazoparib View linked drug · Find medicine records · Find other trials using this name

StatusSUSPENDED

Study typeINTERVENTIONAL

Start date2022-10-21

PhasePHASE1

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)unresolved

Interventions

PidnarulexDRUG

TalazoparibDRUG · verified · RxNorm: talazoparib

Sponsors & collaborators

Peter MacCallum Cancer Centre, Australialead sponsor

Mapped research locations

MelbourneVictoria, Australia2 SydneyNew South Wales, Australia1 Box HillVictoria, Australia1 PrahranVictoria, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05425862 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.